Want to see BLGO full AI Analyst Report?
BLGO Stock Chart & Stats
$0.10
>-$0.01(-0.58%)
At close: 4:00 PM EDT
$0.10
>-$0.01(-0.58%)
Day’s Range― - ―
52-Week Range$0.08 - $0.20
Previous CloseN/A
Volume10.78K
Average Volume (3M)439.15K
Market Cap
$27.61M
Enterprise Value$39.76
Total Cash (Recent Filing)$2.19M
Total Debt (Recent Filing)$6.39M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Nov 18, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding328,731,350
10 Day Avg. Volume337,133
30 Day Avg. Volume439,150
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)14.00
Price to Sales (P/S)7.29
P/FCF Ratio-6.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$5.28M
Bulls Say, Bears Say
Bulls Say
Engineering Business GrowthQuarter-to-quarter engineering revenue growth, alongside management's description of the unit as profitable and essentially self-sufficient, supports a durable operating base. This services platform can help fund commercialization while reducing dependence on parent-company overhead.
Clyra Distribution ExpansionClyra's FDA-cleared platform has established multiple distribution routes covering a substantial portion of its target market, with an initial order already placed. Broader channel access can improve adoption prospects and create a scalable commercial foundation over the next several quarters.
PFAS Commercialization ProgressA first commercial installation and numerous trials indicate that BioLargo's PFAS technology is advancing beyond laboratory development toward market validation. A reference site can strengthen credibility with industrial and municipal customers and support larger project bids over time.
Bears Say
Revenue Contraction And Severe LossesThe sharp revenue decline has reduced the scale available to absorb operating costs, while deeply negative EBIT and net margins show that the current cost base remains far ahead of sales. Unless growth returns and expenses become more efficient, profitability and funding needs will remain pressured.
Heavy Cash BurnPersistent, large operating and free-cash-flow outflows indicate that the business is not yet funding itself through operations. Continued cash burn can constrain investment in commercialization and increase reliance on external capital, making execution more sensitive to financing availability.
Commercial Execution And Funding RiskClyra's delayed launch and disproportionate contribution to consolidated losses show that an important growth initiative is consuming resources before reaching sufficient commercial scale. Required fundraising adds execution risk and could limit the company's ability to sustain the rollout without dilution.
BioLargo News
BLGO FAQ
What was BioLargo Inc’s price range in the past 12 months?
BioLargo Inc lowest stock price was $0.08 and its highest was $0.20 in the past 12 months.
What is BioLargo Inc’s market cap?
BioLargo Inc’s market cap is $27.61M.
When is BioLargo Inc’s upcoming earnings report date?
BioLargo Inc’s upcoming earnings report date is Nov 18, 2026 which is in 47 days.
How were BioLargo Inc’s earnings last quarter?
BioLargo Inc released its earnings results on Aug 17, 2026. The company reported -$0.01 earnings per share for the quarter.
Is BioLargo Inc overvalued?
According to Wall Street analysts BioLargo Inc’s price is currently Overvalued.
Does BioLargo Inc pay dividends?
BioLargo Inc does not currently pay dividends.
What is BioLargo Inc’s EPS estimate?
BioLargo Inc’s EPS estimate is -0.01.
How many shares outstanding does BioLargo Inc have?
BioLargo Inc has 328,731,350 shares outstanding.
What happened to BioLargo Inc’s price movement after its last earnings report?
BioLargo Inc reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of BioLargo Inc?
Currently, no hedge funds are holding shares in BLGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLargo Inc
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.
Technical Analysis
Ownership Overview
12.88% Insiders
0.04% Other Institutional Investors
87.08% Public Companies and
Individual Investors